Inflammation may hold key to why some cancer drugs stop working
NCT ID NCT07241403
Summary
This study looked at 698 patients with advanced colorectal cancer to understand how ongoing inflammation in the body affects a common treatment drug (Bevacizumab) combined with chemotherapy. Researchers measured patients' inflammation levels and tracked how long they lived and how long their cancer stayed under control. The goal was to find clues in the blood that could predict which patients might stop responding to treatment, helping doctors make better treatment choices in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The second hospital of Nanchang university
Nanchang, Jiangxi, 330006, China
Conditions
Explore the condition pages connected to this study.